Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar

Parasite Immunology

Volumn 30, Issue 8, 2008, Pages 403-409

  Ansari, N A ^a   Kumar, R ^a   Raj, A ^a   Salotra, P ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

IgG3; IgG4; Kala azar; Leishmania; Paediatrics; Post Kala azar dermal leishmaniasis

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LEISHMANIASIS; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, PROTOZOAN; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; YOUNG ADULT;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 64549095288     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2008.01036.x     Document Type: Article

References (43)

1. World Health Organization. The Leishmaniasis and Leishmanial HIV co-infections, 2002 http://www.who.int/mediacentre/factsheets/fs116/en/
2. Guerin PJ, Olliaro P & Sundar S. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2: 494-501.
3. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-854.
4. Ansari NA, Ramesh V & Salotra P. IFN-σ, TNF-α, IL-6 and IFN-σRl are the major immunologic determinants associated with post kala azar dermal leishmaniasis. J Infect Dis 2006; 194: 958-965.
5. Atta AM, D'Oliveira A, Correa J, Atta ML, Almeida RP & Carvalho EM. Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis. Am J Trop Med Hyg 1998; 59: 426-430.
6. Anam K, Afrin F, Banerjee D et al. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect Immun 1999; 67: 6663-6669.
7. da Matta VL, Hoshino-Shimizu S, Dietze R & Corbett CE. Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis. J Clin Lab Anal 2000; 14: 5-12.
8. Ravindran R, Anam K, Bairagi BC et al. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun 2004; 72: 863-870.
9. Ryan JR, Smithyman AM, Rajasekariah GH, Hochberg L, Stiteler JM & Martin SK. Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis. J Clin Microbiol 2002; 40: 1037-1043.
10. Bhattacharya SK, Jha TK, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis. Clin Inf Dis 2004; 38: 217-221.
11. Rab MA & Evans DA. Leishmania infantum in the Himalayas. Trans R Soc Trop Med Hyg 1995; 89: 27-32.
12. Ramesh V, ⋯. Misra RS, Saxena U & Mukherjee A. Post-kala-azar dermal leishmaniasis: a clinical and therapeutic study. Int J Dermatol 1993; 32: 272-275.
13. Cillari E, Vitale G, Arcoleo F et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995; 7: 740-745.
14. Ansari NA, Saluja S & Salotra P. Elevated levels of interferon-σ, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119: 339-345.
15. Nylén S & Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 2007; 28: 378-384.
16. Culley FJ, Harris RA, Kaye PM, McAdam KP & Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol 1996; 156: 4691-4696.
17. Smith Bodman KB, Mbuchi M, Culley FJ, Bates PA & Raynes JG. C-reactive protein-mediated phagocytosis of Leishmania donovani promastigotes does not alter parasite survival or macrophage responses. Parasite Immunol 2002; 24: 447-454.
18. Ansari NA, Sharma P & Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. Clin Immunol 2007; 122: 343-348.
19. Kima PE, Constant SL, Hannum L et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000; 191: 1063-1068.
20. Miles SA, Conrad SM, Alves RG, Jeronimo SM & Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005; 201: 747-754.
21. Kane MM & Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166: 1141-1147.
22. Kumar D, Srividya G, Verma S et al. Presence of anti-Lepp12 antibody: a marker for diagnostic and prognostic evaluation of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006; 102: 167-171.
23. Salotra P, Ralhan R & Bhatnagar R. Differential expression of stress proteins in virulent and attenuated promastigotes of Leishmania donovani. Biochem Mol Biol Int 1994; 33: 691-697.
24. Sreenivas G, Raju BV, Singh R et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal leishmaniasis in humans. J Clin Microbiol 2004; 42: 1739-1741.
25. Salotra P, Sreenivas G, Nasim AA, Subba Raju BV & Ramesh V. Evaluation of enzyme-linked immunosorbent assay for diagnosis of post kala-azar dermal leishmaniasis with crude or recombinant K39 antigen. Clin Diagn Lab Immunol 2002; 9: 370-373.
26. Alam SN & Mukhopadhyaya AK. An epidemiological study on post kala azar dermal leishmaniasis in parts of Bihar (India). Indian J Parasitol 1989; 13: 295-297.
27. Neogy AB, Nandy A, Dastidar BG & Chowdhury AB. Antibody kinetics in kala-azar in response to treatment. Ann Trop Med Parasitol 1987; 81: 727-729.
28. Tewary P, Sukumaran B, Saxena S & Madhubala R. Immunos-timulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 2004; 22: 3053-3060.
29. Singh R, Kumar D, Ramesh V, Negi NS, Singh S & Salotra P. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis 2006; 194: 302-306.
30. Ghosh AK, Dasgupta S & Ghose AC. Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis. Clin Diagn Lab Immunol 1995; 2: 291-296.
31. Iskander R, Das PK & Aalberse RC. IgG4 antibodies in Egyptian patients with schistosomiasis. Int Arch Allergy Appl Immunol 1981; 66: 200-207.
32. Anderson CF & Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fcγ receptors. J Immunol 2002; 168: 3697-3701.
33. Brière F, Servet-Delprat C, Bridon JM, Saint-Remy JM & Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994; 179: 757-762.
34. Musa AM, Khalil EA, Raheem MA iet al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immuno-logical and prognostic features. Ann Trop Med Parasitol 2002; 96:765-772.
35. Elassad AM, Younis SA, Siddig M, Grayson J, Petersen E & Ghalib HW. The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin Exp Immunol 1994; 95: 294-299.
36. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H & de Vries JE. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991; 173: 747-750.
37. Kitani A & Strober W. Regulation of C γ subclass germ-line transcripts in human peripheral blood B cells. J Immunol 1993; 151: 3478-3488.
38. Sundar S, Reed SG, Sharma S, Mehrotra A & Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997; 56: 522-525.
39. Ismail A, El Hassan AM, Kemp K et al. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999; 189: 615-622.
40. Singh UK, Patwari AK, Sinha RK & Kumar R. Prognostic value of serum C-reactive protein in kala-azar. J Trop Pediatr 1999; 45: 226-228.
41. Yang J, Wezeman M, Zhang X et al. Human C-reactive protein binds activating Fcγ receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007; 12: 252-265.
42. Yang Z, Mosser DM & Zhang X. Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. J Immunol 2007; 178: 1077-1085.
43. O'Neal SE, Guimarães LH, Machado PR et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 2007; 195: 142-148.